Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics nd oral bioavailability in human volunteers: A stable isotope study

Toxicological Sciences

Volumn 92, Issue 1, 2006, Pages 42-50

  Schultz, Irvin R ^a,c   Shangraw, Robert E ^b  

^a Battelle Pacific NW Division ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Chlorination; GST zeta; Haloacetic acids

Indexed keywords

CARBON; CARBON 13; DICHLOROACETIC ACID; DRINKING WATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; DISINFECTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; FLUID INTAKE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; SEX DIFFERENCE; VOLUNTEER; WATER CONTAMINATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON ISOTOPES; DICHLOROACETATE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; WATER SUPPLY;

RODENTIA;

EID: 33745627047     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj193     Document Type: Article

References (43)

1. Abbas, R., and Fisher, J. W. (1997). A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharmacol. 147, 15-30.
2. Ammini, C. V., Fernandez-Canon, J., Shroads, A. L., Cornett, R., Cheung, J., James, M. O., Henderson, G. N., Grompe, M., and Stacpoole, P. W. (2003).Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem. Pharmacol. 66, 2029-2038.
3. Anderson, W. B., Board, P. G., Gargano, B., and Anders, M. W. (1999). Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem. Res. Toxicol. 12, 1144-1149.
4. Arora, H., LeChevallier, M. W., and Dixon, K. L. (1997). DBP occurrence survey. J. Am. Water Works Assoc. 89, 60-68.
5. Blackburn, A. C., Coggan, M., Tzeng, H. F., Lantum, H., Polekhina, G., Parker, M. W., Anders, M. W., and Board, P. G. (2001). GSTZ1d: A new allele of glutathione transferase zeta and maleylacetoacetate isomerase. Pharmacogenetics 11, 671-678.
6. Blackburn, A. C., Tzeng, H., Anders, M. W., and Board, R G. (2000). Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis. Pharmacogenetics 10, 49-57.
7. Bluck, L. J., Izzard, A. P., and Bates, C. J. (1996). Measurement of ascorbic acid kinetics in man using stable isotopes and gas chromatography/mass spectrometry. J. Mass Spectrom. 31, 741-748.
8. Curry, S. H., Chu, P. I., Baumgartner, T. G., and Stacpoole, P. W. (1985). Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin. Pharmacol. Ther. 37, 89-93.
9. Curry, S. H., Lorenz, A., Chu, P., Limacher, M., and Stacpoole, P. W. (1991). Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm. Drug Dispos. 12, 375-390.
10. Fox, A. W., Sullivan, B. W., Buffini, J. D., Neichin, M. L., Nicora, R., Hoehler, F. K., O'Rourke., R., and Stoltz, R. R. (1996). Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J. Pharmacol. Exp. Ther. 279, 686-693.
11. Gabrielsson, J., and Weiner, D. (2000). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, pp. 415-423, 3rd ed. Model PK10. Swedish Pharmaceutical Press, Stockholm, Sweden.
12. Gibaldi, M., and Perrier, D. (1982). Pharmacokinetics, p. 487. Marcel Dekker, Inc., New York.
13. Gonzalez-Leon, A., Schultz, I. R., and Bull, R. J. (1997). Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prolonged administration in drinking water. Toxicol. Appl. Pharmacol. 146, 189-195.
14. Jia, M., Wu, W. W., Yost, R. A., Chadik, P. A., Stacpoole, P. W., and Henderson, G. N. (2003). Simultaneous determination of trace levels of nine haloacetic acids in biological samples as their pentafluorobenzyl derivatives by gas chromatography-Tandem mass spectrometry in electron-capture negative ion chemical ionization mode. Anal. Chem. 75, 4065-4080.
15. Henderson, G. N., Curry, S. H., Derendorf, H., Wright, E. C., and Stacpoole, P. W. (1997). Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J. Clinical Pharmacol. 37, 416-425.
16. Kaydos, E. H., Suarez, J. D., Roberts, N. L., Bobseine, K., Zucker, R., Laskey, J., and Klinefelter, G. R. (2004). Haloacid induced alterations in fertility and the sperm biomarker SP22 in the rat are additive: Validation of an ELISA. Toxicol. Sci. 81, 430-442.
17. Kim, H., and Weisel, C. P. (1998). Dermal absorption of dichloro- and trichloroacetic acids from chlorinated water. J. Expo. Anal. Environ. Epidemiol. 8, 555-575.
18. Komulainen, H. (2004). Experimental cancer studies of chlorinated byproducts Toxicology 198, 239-248.
19. Lantum, H. B. M., Liebler, D. C., Board, P. G., and Anders, M. W. (2002c). Alkylation and inactivation of human glutathione transferase zeta (hGSTZ1-1) by maleylacetone and fumarylacetone. Chem. Res. Toxicol. 15, 707-716.
20. Loos, R., and Barcelo, D. (2001). Determination of haloacetic acids in aqueous environments by solid-phase extraction followed by ion-pair liquid chromatography-electrospray ionization mass spectrometric detection. J. Chromatogr. A 938, 45-55.
21. Lukas, G., Vyas, K., Brindle, S. D., Le Sher, A. R., and Wagner, W. E. (1980). Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. J. Pharmacol. Sci. 69, 419-421.
22. Pourmoghaddas, H., Stevens, A. A., Kinman, R. N., Dressman, R. C., Moore, L. A., and Ireland, J. C. (1993). Effects of bromide ion on formation of HAAs during chlorination. J. Am. Water Works Assoc. 85, 82-87.
23. Rubin, G. M., Waschek, J. A., Pond, S. M., Effeney, D. J., and Tozer, T. N. (1987). Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J. Pharmacokinet. Biopharm. 15, 615-631.
24. Saghir, S. A., and Schultz, I. R. (2002). Low dose oral bioavailability of dichloroacetate in naïve and GST-zeta depleted F344 rats. Environ. Health Perspect. 110, 757-763.
25. Saghir, S. A., and Schultz, I. R. (2005). Pharmacokinetics and oral bioavailability of halogenated acetic acids from two mixtures in naïve and GST-zeta depleted rats. Toxicol. Sci. 84, 214-224.
26. Schultz, I. R., Merdink, J. L., Gonzalez-Leon, A. G., and Bull, R. J. (1999). Comparative toxicokinetics of chlorinated and brominated haloacids in F344 rats. Toxicol. Appl. Pharmacol. 158, 103-114.
27. Schultz, I. R., Merdink, J. L., Gonzalez-Leon, A. G., and Bull, I. R. (2002). Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: Dose response relationships and age as a modifying factor. Toxicology 173, 229-247.
28. Schultz, I. R., and Sylvestor, S. (2001). Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: Effect of GST-zeta depletion. Toxicol. Appl. Pharmacol. 175, 104-113.
29. Shangraw, R. E., and Fisher, D. M. (1996). Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. Anesthesiology 84, 851-858.
30. Shangraw, R. E., and Fisher, D. M. (1999). Pharmacokinetics and pharmacodynamics of dichloroacetate in healthy volunteers and in patients with cirrhosis. Clin. Pharmacol. Ther. 66, 380-390.
31. Stacpoole, P. W., Harman, E. M., Curry, S. H., Baumgartner, T. G., and Misbin, R. I. (1983). Treatment of lactic acidosis with dichloroacetate. N. Engl. J. Med. 309, 390-396.
32. Stacpoole, P. W., Henderson, G. N., Yan, Z., Cornett, R., and James, M. O. (1998a). Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab. Rev. 30, 499-539.
33. Stacpoole, P. W., Henderson, G. N., Yan, Z., and James, M. O. (1998b). Clinical pharmacology and toxicology of dichloroacetate. Environ. Health Perspect. 106(Suppl. 4), 989-994.
34. Tong, Z., Board, P. G., and Anders, M. W. (1998). Glutathione transferase zeta-catalyzed biotransformation of dichloroacetic acid and other alphahaloacids. Chem. Res. Toxicol. 11, 1332-1338.
35. Tzeng, H., Blackburn, A. C., Board, R G., and Anders, M. W. (2000). Polymorphism and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem. Res. Toxicol. 13, 231-236.
36. Yamaoka, K., Nakagawa, T., and Uno, T. (1978). Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm 6, 547-558.
37. Uden, P. C., and Miller, J. W. (1983). Chlorinated acids and chloral hydrate in drinking water. J. Am. Water Works Assoc. 75, 524-527.
38. United States EPA (1998). National primary drinking water regulations: Disinfectants and disinfection byproducts; final rule. Fed. Regist. 63, 69389-69476.
39. Weinberg, H., Krasner, S., Richardson, S., and Thruston, A., Jr. (2002). The Occurrence of Disinfection By-products (DBPs) of Health Concern in Drinking Water: Results of a Nationwide DBP Occurrence Study, pp. 53-54. http://www.epa.gov/athens/publications/reports/EPA_600_R02_068.pdf.
40. Wells, P. G., Moore, G. W., Rabin, D., Wilkinson, G. R., Oates, J. A., and Stacpoole, P. W. (1980). Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia 19, 109-113.
41. Williams, D. T., Lebel, G. L., and Benoit, F. M. (1997). Disinfection by-products in Canadian drinking water. Chemosphere 34, 299-316.
42. Williams, P. J., Lane, J. R., Turkel, C. C., Capparelli, E. V., Dziewanowska, Z., and Fox, A. W. (2001). Dichloroacetate: Population pharmacokinetics with a pharmacodynamic sequential link model. J. Clin. Pharmacol. 41, 259-267.
43. Zoli, M., Magalotti, D., Bianchi, G., Ghigi, G., Orlandini, C., Grimaldi, M., Marchesini, G., and Pisi, E. (1995). Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. J. Hepatol. 23, 129-134.